Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ OTHER INFECTIOUS DISEASES — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%

Similar metrics at other companies

Eli Lilly logo
LLYOther immunology — Revenue
$470M+44.2%
Gilead Sciences logo
GILDOther HIV — Total revenues
$73M-19.8%
SRT
SRTAOther Clinical — Revenue
$9.95M—
Amgen logo
AMGNOther products — Total revenues
$1.53B+3.6%
NAG
NAGEPharmaceuticals segment — Sales, net
$0—
Arcus Biosciences logo
RCUSOther — Total revenues
$2M—

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other infectious diseases — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's OTHER INFECTIOUS DISEASES — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported OTHER INFECTIOUS DISEASES — sales to customers (note 9) of $37M in Q1 2026.
How has Johnson & Johnson's OTHER INFECTIOUS DISEASES — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's OTHER INFECTIOUS DISEASES — sales to customers (note 9) decreased by 9.8% year-over-year, from $41M to $37M.
What is the long-term trend for Johnson & Johnson's OTHER INFECTIOUS DISEASES — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's OTHER INFECTIOUS DISEASES — sales to customers (note 9) has grown at a -16.7% compound annual growth rate (CAGR), from $363M to $175M.
What does OTHER INFECTIOUS DISEASES — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of pharmaceutical products specifically categorized under the Other Infectious Diseases portfolio. It reflects the market demand and commercial performance of therapeutic agents targeting infectious conditions outside of the company's primary focus areas. This figure is a key indicator of the revenue contribution from niche or secondary infectious disease assets within the broader pharmaceutical segment.